Claudia De Lorenzo is an Associate Professor at the Department of Molecular Medicine and Medical Biotechnology, University "Federico II", and a group leader at CEINGE, Napoli, Italy. After her degree in Biological Sciences and a Ph.D. in Biochemistry and Molecular Biology, she has been working as a visiting fellow, funded by CIB (Consorzio Interuniversitario Biotecnologie), at the Department of Immunology, Imperial College School of Medicine, and the Hammersmith Hospital, London, U.K. She is also a full time researcher at the University of Napoli "Federico II" where she has directed her interests towards anti-cancer immunotherapy. Her research group has world-wide recognition in the discovery and characterization of novel human immunoagents and associated translational biology aspects. Claudia is a co-author of several patents. She has been awarded a prize as young researcher by Italian Foundation for Cancer research "Guido Berlucchi". More recently she has directed her research activity at investigating the molecular basis of the different cardiotoxic effects among the ErbB2 inhibitors by testing their effects in vitro on rat and human cardiomyocytes and in vivo on a mouse model. Her present research interest is focused in the development of novel human immunoconjugates and immune-modulators and their use in immune-oncology approaches as well as novel antibody discovery activities using phage display technologies. These novel antibodies are specific for new tumour associated antigens and other targets useful for diagnosis and/or therapy of different diseases.

 translational biology, immunotherapy, molecular medicine, medical biotechnology